Post-treatment HCC imaging just got clearer. The updated 2024 LI-RADS TR algorithm refines criteria for radiation vs non-radiation therapies and adds MRI features to better detect viable tumor, key for accurate response assessment and management.

Multiple locoregional therapies are available for HCC, with imaging findings specific to each modality. The updated 2024 CT and MRI LI-RADS TR assessment criteria provided distinct algorithms for use after nonradiation or radiation-based therapies, simplified the definition of viable disease, and incorporated MRI ancillary features to enhance detection of tumor viability. These updated criteria can improve diagnostic accuracy, resulting in more effective clinical management of HCC.